Trials / Terminated
TerminatedNCT04772053
Molecular Disease Characterization Initiative (MDCI)
A Global, Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm interventional molecular analysis study with no administration of investigational product and no masking. This multicenter study will involve participants with advanced/metastatic disease for the purpose of collecting tumor tissue and blood samples for broad molecular analysis and examining the expression of specific biomarkers using validated clinical assays.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Tumor biopsy | Archived or fresh tumor biopsy samples will be collected. |
Timeline
- Start date
- 2021-05-25
- Primary completion
- 2022-11-15
- Completion
- 2022-11-15
- First posted
- 2021-02-26
- Last updated
- 2024-04-19
- Results posted
- 2024-04-19
Locations
2 sites across 2 countries: United States, Spain
Source: ClinicalTrials.gov record NCT04772053. Inclusion in this directory is not an endorsement.